StockNews.com began coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a research note released on Wednesday morning. The brokerage issued a sell rating on the stock.
OCX has been the subject of a number of other reports. Benchmark restated a speculative buy rating and set a $5.00 price objective on shares of OncoCyte in a research note on Monday, April 15th. Stephens restated an equal weight rating and set a $4.00 price objective on shares of OncoCyte in a research note on Wednesday, April 17th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, OncoCyte currently has a consensus rating of Hold and an average price target of $4.06.
View Our Latest Research Report on OncoCyte
OncoCyte Price Performance
Insider Buying and Selling at OncoCyte
In other OncoCyte news, major shareholder Broadwood Partners, L.P. acquired 2,420,000 shares of the company’s stock in a transaction on Thursday, April 11th. The shares were bought at an average cost of $2.92 per share, with a total value of $7,066,400.00. Following the completion of the acquisition, the insider now owns 4,929,066 shares in the company, valued at $14,392,872.72. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other OncoCyte news, major shareholder Broadwood Partners, L.P. acquired 2,420,000 shares of the company’s stock in a transaction on Thursday, April 11th. The shares were bought at an average cost of $2.92 per share, with a total value of $7,066,400.00. Following the completion of the acquisition, the insider now owns 4,929,066 shares in the company, valued at $14,392,872.72. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Andrew Arno acquired 33,898 shares of the company’s stock in a transaction on Thursday, April 11th. The stock was acquired at an average cost of $2.95 per share, for a total transaction of $99,999.10. Following the completion of the acquisition, the director now owns 69,054 shares of the company’s stock, valued at approximately $203,709.30. The disclosure for this purchase can be found here. Over the last ninety days, insiders acquired 2,457,288 shares of company stock worth $7,176,400. 1.94% of the stock is owned by insiders.
About OncoCyte
OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay.
Further Reading
- Five stocks we like better than OncoCyte
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- MarketBeat Week in Review – 4/22 – 4/26
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- 3 Stocks Leading the U.S. Agriculture Comeback
- What does consumer price index measure?
- How to Use Put Debit Spreads to Profit From Falling Stocks
Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.